Patheon to Acquire Banner Pharmacaps - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Patheon to Acquire Banner Pharmacaps

Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million. The acquisition will provide Patheon with several new products, technologies and facilities, and is also in line with the company’s intention to further develop its oral dosage development and manufacturing services.

According to a press statement, Banner Pharmacaps is the second largest pharmaceutical business in the world focused on developing softgel formulations. The company has research laboratories and manufacturing facilities in the US, the Netherlands, Canada and Mexico.

James C. Mullen, CEO of Patheon, said in the statement, “The transaction provides is with a well-balanced portfolio of proprietary products, state-of-the-art facilities with enhanced capabilities, as well as an expanded geographical presence. We believe our visibility with in the industry will be further strengthened as we pass the $1-billion revenue mark.”

Patheon is purchasing Banner Pharmacaps from VION N.V., a manufacturer of foodstuffs and ingredients based in the Netherlands. VION intends to now focus on its core business in the food industry.

The acquisition is expected to close by the end of this year.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here